Remove DEA Remove Programs Remove Research and Development
article thumbnail

What Could Rescheduling Mean for Medical Cannabis Patients?

Canna Care Docs

Drug Enforcement Administration (DEA) will move to reclassify cannabis — a historic shift that could have wide ripple effects across the country. Understanding current drug scheduling for cannabis The DEA classifies drugs, substances, and certain chemicals used to make drugs into five distinct categories or “schedules.”

Patients 111
article thumbnail

Intoxicating Hemp Swindle

Project CBD

What’s more, synthesized Delta-9 THC is present in many of these products, despite being prohibited in both California’s cannabis and hemp programs. She sees a potential for vape-related lung damage similar to the nationwide outbreak of hundreds of pulmonary injuries, some fatal, that researchers linked to vaping in 2019.

Hemp 232
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Check out ASA's May Newsletter!

Americans for Safe Access

Our lead story addresses the ISO 17065 Accreditation of our PFC program and explains why PFC becoming the first cannabis certification body to have achieved this matters so much. You will also find out how to access the recorded panels from Unity 2021 to catch anything you missed.

article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

article thumbnail

Press Release: Cybin Granted DEA Schedule I Manufacturing License

Cannabis Law Report

Cybin Granted DEA Schedule I Manufacturing License. Drug Enforcement Agency (“DEA”). The DEA license is a federal requirement for any investigators who intend to study, produce, analyze or otherwise work with Schedule I controlled substances. The DEA license is for the Company’s research lab in the Boston area.

DEA 52
article thumbnail

Clever Leaves and Biopharmaceutical Research Company to Partner for Landmark Cannabis Research Study in Collaboration with the University of California, Davis

Cannabis Law Report

The initiative is part of Project Change Lives; Clever Leaves’ $25M product pledge to aid cannabis research in the U.S. The collaboration represents the Company’s first funded study with a research institution in the United States. organization to help advance scientific research into the potential medical benefits of cannabinoids.

article thumbnail

DEA Faces Lawsuit For Denying End of Life Patients the Right to Try Psychedelics Therapy

Veriheal

Did we ever stop to think that if we could legally utilize the plants in the first place that perhaps we wouldn’t develop terminal illnesses at such a high rate? The FDA refers to this program as the expanded access program on their website. Introducing the Right to Try Act. Sunil Aggarwal was also named in the lawsuit.

Therapy 64